Whether you need mammograms after 70 depends less on your age and more on your overall health and how long you’re likely to live. No major medical organization draws a hard stop at 70, but guidelines diverge sharply on when screening should end, and the evidence becomes genuinely murky for women over 75 because randomized trials have largely excluded them. The result is a real gap between what we know and what doctors are asked to recommend, and filling that gap requires an honest look at the tradeoffs involved.
What the Major Guidelines Actually Say
The disagreement among medical organizations is striking and worth understanding, because your doctor’s recommendation may depend partly on which set of guidelines they follow. The US Preventive Services Task Force, which drives much of primary care policy, recommends biennial screening mammography for women aged 40 through 74 and states that evidence is insufficient to assess the balance of benefits and harms for women 75 and older. That is not a recommendation to stop; it is an acknowledgment that the task force lacks the data to say either way.
Other organizations are more permissive. The American Cancer Society recommends continuing screening as long as a woman’s overall health is good and she has a life expectancy of ten years or longer. The American College of Obstetricians and Gynecologists recommends screening until at least age 75 and says decisions beyond that age should be based on the woman’s health and longevity. The American College of Radiology goes furthest, recommending annual screening with no upper age limit, unless severe health problems limit life expectancy.1JAMA. Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement – Section: Recommendations of Others
The practical takeaway is that turning 70, or even 75, does not trigger a guideline-based reason to stop mammography. What triggers the conversation is a shift in your health status.
Does Screening After 75 Actually Reduce Deaths?
The honest answer is that the evidence points in that direction but is not as clean as it is for younger women. No large randomized trial has ever been completed exclusively in women 75 and older, so researchers rely on observational studies, which carry more uncertainty. A review of available data found that older women undergoing regular mammography experienced significant reductions in breast cancer mortality, except among those with severe health problems or limited life expectancy.2PubMed. Screening for Breast Cancer in Women Age 75 Years and Older
A systematic review published in 2023 looked specifically at the benefits and harms of mammography screening in women 75 and older and found a complicated picture. Some studies showed that women whose cancers were found by screening had roughly half the risk of dying from breast cancer compared with women whose cancers were detected other ways. As the gap between mammograms lengthened, the risk of breast cancer death increased: women who went more than five years between screens, or who never screened, had about two to three times the risk compared with regular screeners. Yet other studies found no significant mortality difference between screened and unscreened older women.3British Journal of Cancer. Health benefits and harms of mammography screening in older women (75+ years)—a systematic review
The split in findings likely reflects differences in health status among the women studied. A healthy 78-year-old and a frail 78-year-old with multiple chronic conditions are essentially different populations when it comes to screening benefits.
The Overdiagnosis Problem Gets Bigger With Age
Overdiagnosis refers to finding a cancer through screening that would never have caused symptoms or shortened the person’s life. It is a real phenomenon at every screening age, but it becomes a much larger concern after 70 because the odds of dying from something other than breast cancer increase with each passing year.
A major US study estimated the scale of this problem. Among women aged 70 to 74 who underwent screening, roughly 31 percent of detected breast cancers may have been overdiagnosed. That number climbed to about 47 percent for women aged 75 to 84 and about 54 percent for women 85 and older.4PubMed Central. Estimating Breast Cancer Overdiagnosis after Screening Mammography among Older Women in the US Those are sobering numbers. They mean that among the oldest screened women, more than half of newly diagnosed breast cancers may never have become a health problem during their lifetimes. The issue is of greater significance in older women precisely because competing causes of death are more common.5PubMed Central. Overdetection of Breast Cancer
The trouble with overdiagnosis is that once a cancer is found, it is very difficult for a doctor to tell a patient it probably doesn’t need treatment. Nearly all detected cancers are treated, which means overdiagnosed women may undergo surgery, radiation, or hormonal therapy for a disease that would never have harmed them.
Earlier Detection Still Matters for Healthy Older Women
On the other side of the ledger, screening mammography does catch cancers at earlier stages in older women who continue to get screened. A study of elderly women found that those who were persistent with screening were significantly more likely to be diagnosed at earlier stages. Compared with women who were not persistent, screened women had more than three times the odds of being diagnosed with in situ disease, about twice the odds of being diagnosed at a local stage, and about 60 percent higher odds of being diagnosed at a regional stage rather than at a distant, harder-to-treat stage.6PubMed Central. Association between persistence with mammography screening and stage at diagnosis among elderly women diagnosed with breast cancer
Earlier-stage cancers are easier and less invasive to treat, require less aggressive therapy, and come with a better prognosis. For a woman in good health who could tolerate treatment, finding a cancer at stage I rather than stage III is a meaningful difference in outcome and quality of life.
What Breast Cancer Looks Like in Older Women
Breast cancer biology shifts with age in ways that cut both directions. Research comparing tumors in older and younger women found that older women’s cancers tend to have lower levels of Ki67, a marker of how fast tumor cells are dividing, and higher levels of BCL2, a protein associated with slower-growing, less aggressive disease. Older women’s tumors also showed lower expression of EGFR and p53, which are linked to more aggressive cancer types.7PubMed Central. Biology of primary breast cancer in older women beyond routine biomarkers
In plain terms, breast cancer in older women is more often slow-growing and hormone-receptor positive. These are the types that respond well to hormonal therapy and are less likely to spread quickly. That biological reality feeds into the overdiagnosis concern: a slow-growing tumor found at age 82 may simply never reach a point where it threatens that woman’s life. But it also means that when a screen does catch an aggressive cancer in an older woman, early detection can make a real difference because aggressive tumors at any age benefit from prompt treatment.
False Positives, Biopsies, and Anxiety
Mammography is not just about what it finds. The screening process itself carries costs, and those costs accumulate over years. A long-running study estimated that after ten mammograms, roughly half of women who do not have breast cancer will have received at least one false-positive result. About 19 percent will have undergone at least one biopsy prompted by those false alarms.8PubMed. Ten-year risk of false positive screening mammograms and clinical breast examinations
The emotional toll of a false positive is real. Among women who received one, about half reported moderate or higher levels of anxiety, and about 5 percent described their anxiety as extreme. About 15 percent of women with a false positive underwent a biopsy procedure.9PubMed Central. Consequences of False-Positive Screening Mammograms For an older woman who has already had decades of screening, one more false positive may feel like a smaller deal. But for women who are frail, anxious about medical procedures, or have cognitive concerns, the downstream testing from a false alarm can be genuinely burdensome.
That said, the long-term psychological impact may be smaller than you’d expect. Research found that undergoing a biopsy or follow-up after a false positive did not have large lasting psychosocial effects and did not deter women from continuing to screen.10PubMed. Does biopsy, aspiration or six-month follow-up of a false-positive mammogram reduce future screening or have large psychosocial effects? The anxiety spike is typically short-lived for most women, though individual responses vary.
Health Status Matters More Than the Number on Your Birthday
The clearest finding across all this research is that health status, not age alone, should drive the decision. A cost-effectiveness analysis found that extending biennial mammography from age 75 to age 80 for women with no major chronic conditions prevented about 1.7 breast cancer deaths per 1,000 screened women and added roughly six days of life expectancy per woman, at a cost that fell below the standard threshold for worthwhile healthcare spending. For women with one major chronic condition, the benefit dropped to about 1.4 deaths averted and four extra days of life. For women with two or more chronic conditions, benefits fell further while harms stayed relatively constant.11PubMed Central. Cost-Effectiveness of Screening Mammography Beyond Age 75 Years
That same analysis found that overdiagnosis was more common than deaths averted at every health level: even among the healthiest women, about 3.2 per 1,000 were overdiagnosed compared with 1.7 deaths prevented. The ratio tilts further toward harm as health worsens. For women with two or more chronic conditions, 2.2 per 1,000 were overdiagnosed while only 1.0 death was averted.11PubMed Central. Cost-Effectiveness of Screening Mammography Beyond Age 75 Years
The life-expectancy threshold that several organizations use, generally about ten years, serves as a rough filter. A woman in her early 70s with no serious health problems likely has well over a decade of life remaining, and screening probably still makes sense. A woman in her early 70s with heart failure, advanced diabetes, and significant mobility limitations may have a shorter expected lifespan, and the chance that a new breast cancer diagnosis would outpace her other health conditions is lower.
Modeling Studies and the Tradeoff Math
Researchers have used mathematical models to simulate the population-level consequences of different screening strategies. One modeling study compared three approaches: annual screening from 40 to 84, a hybrid approach (annual from 45 to 54 then biennial to 79), and biennial screening from 50 to 74. The most aggressive strategy delivered the largest mortality reduction, around 40 percent, but it also produced the highest numbers of false-positive recalls and unnecessary biopsies.12PubMed. Comparison of recommendations for screening mammography using CISNET models
These models are useful for understanding the shape of the tradeoff, but they carry real uncertainty. A separate study found that five different breast cancer models, all using the same input data, predicted a wide range of outcomes: mortality reductions from a hypothetical perfect screening test varied from 33 to 67 percent depending on the model.13PubMed Central. Comparing CISNET Breast Cancer Models Using the Maximum Clinical Incidence Reduction Methodology That spread tells you that even the best modeling tools disagree substantially, which helps explain why guidelines from different organizations land in different places.
Having the Conversation With Your Doctor
Given the uncertainty, shared decision-making is the approach that most guidelines recommend for women over 75, and it is arguably a good idea for anyone over 70. Shared decision-making means your doctor presents the potential benefits and harms, considers your specific health situation, and you make the choice together rather than following a blanket rule.
Researchers have developed conversation aids specifically for women 75 and older to help structure these discussions. In one study testing such a tool, patients rated the decision-making process highly. After the conversation, seven patients chose to stop screening, nine decided to screen less frequently, and 14 chose to continue screening regularly.14PubMed Central. Creating a Mammography Conversation Aid for Shared Decision-Making Between Clinicians and Women Aged 75 and Older The fact that decisions went in all three directions illustrates the point: there is no single right answer for all older women.
Primary care providers themselves recognize the difficulty. A qualitative study found that clinicians saw decision tools as potentially vital for ensuring older patients could make informed choices about continued screening.15Preventive Medicine Reports. Primary care provider perspectives on screening mammography in older women: A qualitative study The conversation can feel uncomfortable because nobody wants to hear that their doctor is weighing whether the test is still worth it. But the discomfort of that discussion is far smaller than the discomfort of unnecessary treatment triggered by an overdiagnosed cancer.
Newer Imaging Technology May Shift the Balance
One factor that could improve the benefit-to-harm ratio for older women is advances in mammography technology. Digital breast tomosynthesis, sometimes called 3D mammography, generates images in thin slices through the breast rather than a single flat image. A review of the evidence found that tomosynthesis increases cancer detection rates while decreasing recall rates and false positives compared with standard two-dimensional mammography.16PubMed Central. Pros and cons for breast cancer screening with tomosynthesis – a review of the literature
Fewer false positives is particularly valuable for older women, since reducing unnecessary follow-up procedures and biopsies lowers the harm side of the equation without cutting into the benefit side. As tomosynthesis becomes more widely available, the calculus for screening older women could tilt somewhat more toward benefit, though no study has yet looked specifically at how this technology changes outcomes in women over 75.
Disparities in Who Gets Screened and Who Doesn’t
The debate over when to stop screening assumes all women have equal access to mammography in the first place. That is not the case. A longitudinal study of Medicare beneficiaries in Texas found significant racial and geographic disparities in screening use. Rural Hispanic women were about 33 percent less likely to be regular mammography users compared with their urban counterparts, and rural non-Hispanic Black women were about 22 percent less likely.17PubMed Central. Rural racial disparities and barriers in mammography utilization among Medicare beneficiaries in Texas: A longitudinal study
These disparities mean that some older women are effectively making the decision to stop screening not by choice but because of barriers to access. For women in underserved communities who have screened irregularly or not at all, the considerations are different. A woman who has never had regular mammograms and reaches 72 in good health might benefit from starting or resuming screening, because she has not had the years of surveillance that her regularly screened peers have had. The conversation about stopping screening is only meaningful if you had the option of screening in the first place.
Questions Worth Asking Yourself
If you’re over 70 and trying to decide whether to continue screening, a few practical questions can help frame your thinking:
- Overall health: Do you have major chronic conditions like heart failure, advanced lung disease, or poorly controlled diabetes that are likely to affect your lifespan more than a potential new breast cancer diagnosis?
- Functional status: Could you reasonably tolerate breast cancer treatment, including surgery and possibly radiation or hormonal therapy, if a cancer were found?
- Personal risk factors: Do you have a strong family history of breast cancer, dense breast tissue, or other factors that put you at above-average risk? Higher-risk women may get more benefit from continued screening.
- Your values: How do you weigh the possibility of catching a cancer early against the possibility of being treated for something that would never have harmed you? There is no objectively correct answer here.
These questions are more useful than any single age cutoff. A vigorous 80-year-old with no major health conditions and a family history of breast cancer has a different risk profile than a 72-year-old managing several serious chronic illnesses. The screening decision should reflect that difference, and a good doctor will help you work through it rather than defaulting to a blanket recommendation in either direction.